Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2140023 randomized withdrawal study in adults with schizophrenia
2011-002292-41Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pomaglumetad methionil in schizophrenia, sponsored by Eli Lilly and Company. Started Sep 2011; status: completed.
02
Drugs
pomaglumetad methionil
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2011-002292-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002292-41.